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Lymphopenic insult has been shown to precipitate the initiation of autoimmune disease
in murine models such as the Non-obese diabetic mouse. Similarly, in man lymphopenia
induced by mAb therapy, for instance Alemtuzumab as treatment for Multiple Sclerosis,
can precipitate development of secondary autoimmune disease in up to 30 % of
patients. We asked whether an identified autoimmune susceptibility locus might increase
the risk of developing autoimmunity in the context of mAb-induced lymphopenia in
a mouse model. A single nucleotide polymorphism (SNP) in the gene encoding the
tyrosine phosphatase PTPN22 (R620W) is associated with multiple human autoimmune
diseases, and PTPN22 has been shown to modulate T cell responses, particularly
to weak antigens. In keeping with this, PTPN22-deficient or PTPN22 R619W mutant
murine T cells adoptively transferred into immunodeficient lymphopenic hosts showed a
higher lymphopenia-induced proliferation rate than WT cells. We induced lymphopenia
by treating wild-type or PTPN22 knock-out mice with T cell depleting antibodies and
monitored reconstitution of the T cell pool. We found that PTPN22 deficient T cells
acquired a more activated effector phenotype, with significantly more IFNγ producing
cells. This resulted from expansion driven by self-peptide MHC, as it was evident
when the contribution of IL-7 to lymphopenic expansion was blocked with IL-7R Ab.
Interestingly, Foxp3+ Tregs were also considerably expanded in PTPN22-deficient and
PTPN22 R619Wmice, as was the frequency of both CD25+ and CD25− CD4T cells that
produce IL-10. Using bone marrow chimeric mice, we showed that PTPN22 influenced
development of both regulatory and effector T cell functions in a cell-intrinsic manner.
Overall the expansion of Tregs is likely to keep the expanded T effector populations in
check and sparing Treg during therapeutic mAb depletion may be a useful strategy to
prevent occurrence of secondary autoimmunity.
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INTRODUCTION
Lymphopenia can lead to the expansion of autoreactive T cell
clones and thus may be a risk factor for autoimmune diseases.
Studies in mice have shown a direct link between lymphopenia-
induced proliferation (LIP) and the development of diabetes
in non-obese mice and autoimmune pancreatitis after sublethal
irradiation and transfer of auto-antigen specific T cells (1,
2). However, in normal immune-competent mice lymphopenia
induced T cell proliferation is well-tolerated with no signs of
auto-inflammation (3). Thus, lymphopenia itself does not induce
autoimmunity but has the potential, or can be a co-factor, in
triggering autoimmune development by inducing alterations in
the T cell repertoire and the balance between regulatory and
conventional T cells. Initial rebalancing of homeostasis after a
lymphopenic insult is mediated by cell proliferation, which is
driven by recognition of MHC presented self-peptides via the
T cell receptor and the greater availability of cytokines (4).
Lymphopenia is therapeutically induced for hematopoietic
stem cell transplant (HSCT) therapies to treat a wide range
of diseases (5, 6). Often HSCT therapies include lymphocyte
depleting regiments, in order to condition for the subsequent
transplant. Since T cell alloreactivity is a major risk for graft
rejection, T cell depletion is an important preventive strategy in
allogeneic HSCT although it comes with the cost of an increased
risk of infection-mediated disease relapse and auto-inflammatory
complications. However, so far only very limited data is available
that investigates the risk of the development of autoimmune
diseases post-conditioning and HSCT on a mechanistic level.
HSCT is also used to treat autoimmune diseases themselves,
in which intense lymphodepleting condition regiments are used
in order to target autoreactive cells. In a less invasive therapeutic
approach to treat Multiple Sclerosis without undergoing
irradiation, patients received alemtuzumab (Campath-1H), a
monoclonal antibody against CD52. In this approach the
immune system is reconstituted primarily by lymphopenia
induced lymphocyte proliferation. Interestingly one third of
the patients developed secondary autoimmune conditions after
treatment with alemtuzumab, while another third presented
with asymptomatic autoantibodies. Subsequently, Jones et al.
showed that alemtuzumab-induced lymphopenia stimulated
residual T cell expansion and a consequent shift in T cells
toward a chronically activated phenotype with a loss of clonal
diversity (7). Patients that developed a secondary autoimmunity
showed a reduced TCR diversification compared to non-
autoimmune patients. This study was the first to demonstrate
a mechanistic link between lymphopenia induced proliferation
and the development of autoreactive cells by characterizing T cell
reconstitution in a group of lymphodepleted MS patients (7).
Notably, the risk of developing secondary autoimmunity
following lympho-depletion regimes might be increased for
Abbreviations: Ab, antibody; IFN, interferon; IL, interleukin; KO, knock-out;
LIP, lymphopenia induced proliferation; mAb, monoclonal antibody; MHC, major
histocompatibility complex; p, peptide; p. i., post injection; PTPN, protein tyrosine
phosphatase non-receptor; SNP, single nucleotide polymorphism; TCR, T cell
receptor; Treg, regulatory T cell.
these patients given that they started with an underlying
autoimmune disease and therefore may have increased pre-
disposition to self-reactivity. However, it is not understood
why one patient develops secondary autoimmunity whereas
another does not. Given that genome-wide association studies
(GWAS) have identified numerous genetic mutations that act as
risk factors for autoimmune disease, we asked whether genetic
pre-disposition for autoimmunity increased the susceptibility
to develop autoimmunity as a consequence of lymphopenia
induced proliferation.
A single point mutation in the human PTPN22 gene is
associated with a higher risk for several autoimmune diseases
such as rheumatoid arthritis, type 1 diabetes, systemic lupus
erythematosus among others and is the strongest non-HLA risk
factor described to date (8, 9). The PTPN22 gene encodes a
tyrosine phosphatase and is expressed in all hematopoietic cells.
The risk variant PTPN22R620W is relatively common in white
Europeans and their descendants, with the highest incidence
in Finland (15%) followed by Ukraine (14%) (10). The point
mutation is located in the C-terminal domain of the PTPN22
protein, which is highly conserved between mice and men and
functionally important for the interaction with CSK and TRAF3
(8). Studies in mice have demonstrated an important role for
PTPN22 in negatively regulating T cell responsiveness to weak
affinity antigens, resulting in an increased overall T cell number
and an expansion of the memory-effector population in PTPN22
deficient mice (11, 12). A recent study showed that loss of
PTPN22 in isogenic human Jurkat cells resulted in enhanced
expression of IL-2 and CD69 upon antigen stimulation (13).
Given the relative high penetrance of the PTPN22 variant
allele, its association with autoimmunity and most importantly
its role in regulating responses to weak affinity antigens,
we investigated whether alterations in PTPN22 influenced
the restoration of T cell homeostasis following perturbation
in vivo. In keeping with clinical human lymphodepletion
regimes, we induced severe lymphopenia by treating mice with
monoclonal anti-CD4 and anti-CD8 depleting antibodies and
monitored the reconstitution of the T cell pool. In this model
upon reconstitution, PTPN22 deficient T cells acquired an
enhanced activated effector phenotype, with significantly higher
production of IFNγ compared to wildtype T cells. Interestingly
we found that Foxp3+ Tregs are expanded and CD25+ as
well as CD25− CD4T cells expressed higher levels of IL-10,
which may keep the expanded effector population in check.
Our data indicate that maintaining a high Treg:T effector cell
ratio in mAb depletion therapies may be beneficial in preventing
secondary autoimmunity.
MATERIALS AND METHODS
Mice
Introduction of the R619W mutation was carried out by
microinjection of a mix of Cas9 protein, guide RNA and ssDNA
repair oligo (Integrated DNA Technologies) into single cell
embryos generated by mating superovulated PEP-OST OT1
Rag1KO female mice, which contain a One-STrEP-Tag sequence
knocked into the 5′ end of the PTPN22 gene (details below)
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with OT1 Rag1KO studs. Briefly, a 20 nt crRNA with sequence:
AAGACTCGGGTGTCCGTTCA was designed to span the
intended mutation site in exon 14 of PTPN22. This was annealed
to TRACR RNA by heating to 95
◦
C for 5min and allowed to
cool to room temperature before incubation with Cas9 protein
at 37
◦
C for 10min in 0.1 TE buffer. The repair oligo was
subsequently added to a final concentration of 100 ng/µL. The
repair oligo was a 130bp ssDNA ultramer with sequence: CTT
TATTCTTATAAAACATTGCGATTACATTTCTATTACTTG
GTTAGCTCCTTCTCGGAGGACAGATGATGAAATCCCCC
CGCCACTGCCTGAATGGACACCCGAGTCTTTTATTGT
GGTTGAGGAAGCC which differed from the genomic DNA by
three bases. The intended C to T change introduced a new XcmI
restriction digest site and the arginine to tryptophan substitution.
A further two silent mutations in the PAM region for the guide
RNA were introduced to halt any subsequent Cas9 activity at this
site. Introduction of the intended mutations were confirmed by
restriction digest with XcmI and Sanger sequencing.
The PEP-OST OT1 Rag1KO mouse was generated by
constructing a multitask allele of the Ptpn22 gene comprising at
its 5′ end a Twin-Strep-tag-coding sequence which encodes for
the peptide tag OST (One-STrEP-Tag) and a Gly-Ser-Gly spacer
sequence as well as two loxP sites bracketing the modified exon
1 (14). A frt-neor-frt cassette was used for selecting ES cells
containing the edited Ptpn22 allele (15). M8.F6 C57BL/6N ES
cells (16) were electroporated with the targeting vector. After
selection in G418 or in G418 plus ganciclovir, ES cell clones were
screened for proper homologous recombination by Southern blot
and PCR analysis. A probe specific for the neor cassette was also
used to ensure that adventitious non-homologous recombination
events had not occurred in the selected clones. Mutant ES cells
were injected into FVB blastocysts. Excision of the frt-neor-
frt cassette was achieved through cross with transgenic mice
expressing a FLP recombinase under the control of the actin
promoter (15). Screening for the presence of the OST-targeted
alleles was performed by PCR using the following pair of primers:
sense 5′-GCAGTGGCTTCTTGGTGCTG-3′ and antisense 5′-
TGGCAAACTCCTCACTGTTG-3′. The official name given to
those Ptpn22OST mice is B6-Ptpn22tm2Ciphe. Mice carrying the
PEP-OST modification were subsequently back-crossed onto the
Rag1KO OT-I background.
Mice with a global PTPN22 deficiency, were backcrossed>10
times to the C57BL/6J background and crossed to a Rag1KOOT-
I background as previously described (12). Rag1 KO, C57BL6/J,
CD45.1, CD45.1/2, and CD45.2 mice were bred in-house at the
University of Edinburgh. Age-matched (7–12 weeks at start of
experiment) and sex-matched mice were used in all experiments.
Untreated control mice were co-housed with experimental mice
and had a similar age at necropsy. All procedures were approved
under a project license granted by the UK Home Office and
performed in accordance with the institutional and ethical
guidelines of the University of Edinburgh.
Antibody-Mediated T Cell Lymphopenia
To induce severe T cell lymphopenia 100µg anti CD4 (clone YTS
191) and 50 µg of anti CD8 (clone YTS 169.4), both BioXcell
were given intraperitoneally. Where stated, groups of mice were
given 300 µg mAb to IL-7R (clone A7R34; a hybridoma prepared
in-house) intraperitoneally every second day over the 14 days
experimental time-course. The anti CD25 antibody (clone PC61)
was purchased from BioXcell and a single dose of 500µg per
mouse was injected intraperitoneally.
Adoptive T Cell Transfer Experiments
For cell transfer into Rag-1 KO recipient mice, CD45.1 PTPN22
WT, CD45.1/2 PTPN22 R169W, and CD45.2 PTPN22 KO OT-
I T cells were mixed at a ratio of 1:1:1 and a total of 5x10e5
cells were injected intravenously. In some experiments, recipient
mice were lethally irradiated before cell transfer. Mixed bone
marrow chimeras were generated by reconstituting CD45.1/2
PTPN22 WT recipients with T cell depleted bone marrow cells
from CD45.1 PTPN22 WT and CD45.2 PTPN22 KO mice,
mixed at a ratio of 1:1. In other experiments CD45.1/2 recipients
were reconstituted with Rag1 KO bone marrow and received in
addition 2.5x10e5 CD45.1 WT and CD45.2 PTPN22 KO naïve
CD4+CD62L+CD44−CD25− T cells mixed at a ratio of 1:1.
Naïve CD4T cells were obtained by enrichment of CD4+ T cells
using a mouse CD4+ T cell Isolation Kit (Miltenyi), followed
by sorting for naive CD4+CD62L+CD44−CD25− T cells with a
FACSAria sorter (BD).
Flow Cytometry
The following specific antibodies were used: a(anti)CD4
fluorescin isothiocyanate (Fitc), allophycocyanin (APC) or
Pacific Blue (clone RM4-5), aCD4 phycoerythrin (Pe) cyanine
(Cy)7 or Pacific Blue (clone RM4-4), aCD8 Fitc or peridinin
chlorophyll protein (PerCP)/Cy5.5 (clone YTS156.7.7), aCD25
PeCy7 (clone 3C7), aCD45 PerCP/Cy5.5 (clone 30-F11),
aCD45.1 Fitc or APC (clone A20), aCD45.2 PcP, PeCy7 or
Pacific Blue (clone 104), aCD62L Pe, APC or Pacific Blue
(clone MEL-14), aIFNγ Fitc, PeCy7 or APC (clone XMG1.2),
aIL-10 Pe or APC (clone JES5-16E3) and aIL-10R (aCD210)
Pe (clone 1B1.3a) were purchased from BioLegend. aCD8
PeCy7 (clone eBioH35-17.2), aCD25-APC or PeCy7 (clone
PC61.5), aCD44 Alexa eFlour780 (clone IM7), aFoxp3 eFlour
450, Pe or APC (clone FJK-16s) and aT-bet Pe (clone 4B10)
were purchased from eBiosciences. aKi67-PE or Fitc (clone
B56) and aCD4-Fitc (RM4-5) were purchased from BD.
Live/Dead Aqua or Far Red (both Life Technologies) were
used to identify live cells. Intracellular cytokine staining was
performed using Fixation buffer (BioLegend) to permeabilise
and fix cells, for subsequent antibody staining the Intracellular
Perm Wash Buffer (BioLegend) was used. For staining of
transcription factors, cells were permeabilized and fixed in
FoxP3 Fix/Permeabilization Buffer (eBioscience) before staining
with antibodies in Permeabilization/Wash buffer (eBioscience).
Samples were acquired with a Fortessa (BD) or a MACSQuant
flow cytometer (Miltenyi). Data was analyzed with FlowJo
software (Treestar).
Cell Culture and Stimulation
Cells from lymph nodes or spleens were cultured in IMDM
medium supplemented with heat-inactivated 10% FBS, 2mM
L-glutamine, 100U/mL Penicillin, 100mg/mL Streptomycin and
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50µM 2-mercaptoethanol (all Sigma-Aldrich). For in vitro cell
proliferation assays cells were labeled with 500 nM CellTracer
Violet (Life Technologies). N4, T4, and G4 peptides (Peptide
Synthetics) were added to culture medium at indicated
concentrations. Recombinant IL-7 (Peprotech) was used
at 20 ng/mL, recombinant IL-10 (Peprotech) was used at
indicated concentrations. For cytokine recall responses cells were
restimulated with 20 ng/mL phorbol 12,13-dibutyrate (PdBU)
and 0.5µg/mL Ionomycin (all Sigma-Aldrich) in presence
of 1µg/ml Brefeldin A for 4 h before intracellular staining
(antibodies identified above). Transgenic OT-1 T cells were
restimulated with T4 peptide (SIITFEKL) in presence of 1µg/ml
brefeldin A for 4 h. Where stated cells were stimulated in media
with 0.5µg/mL anti CD3ε antibody and 2µg/mL anti CD28
antibody (both BioLegend) for 4 h.
Statistical Analysis
Prism software Version 7 was used for statistical significance
analysis. All data was tested for normality and depending on the
experimental set up a Student’s t-test or a 1way ANOVA with a
Sidak’s multiple comparison test was performed. For experiments
with two factors a 2way ANOVA test was used followed by
Sidak’s multiple comparison test. In experiments in which cells
of different genotypes were adoptively transferred into one host
a paired analysis was used. When a dataset failed to meet the
requirements for a parametric test, a non-parametric unpaired
Kruskal Wallis test with a Dunn’s multiple comparison test was
used. All experiments were repeated at least twice. The figure
legends are stating the number of repeats for each experiment
and how many animals were used.
RESULTS
Similar T Cell Reconstitution in WT and
Ptpn22 KO Mice Following Transient
Lymphopenia
To test whether Ptpn22 regulated homeostatic T cell proliferation
in response to transient lymphopenia in mice we chose an Ab-
mediated lymphopenia model, as this was similar to the mode
of action of drugs such as Alemtuzumab which is used for
lymphodepletion therapy in man. A single injection of 100 µg
CD4 and 50 µg CD8 mAbs per mouse mediates severe T cell
depletion with high specificity (3). At day 3 post injection 90–99%
of CD4 and CD8T cells were depleted in blood, spleen and lymph
nodes (Supplementary Figures 1A,B). The depletion efficacy
was similar in Ptpn22 wildtype (WT) and Ptpn22 knockout (KO)
mice (Supplementary Figures 1A,B). After depletion of T cells,
lymphocyte reconstitution was monitored by blood sampling.
The absence of PTPN22 had very little effect on the overall
kinetics of T cell reconstitution and both PTPN22 WT and KO
CD4T cells reached homeostasis around 4 weeks after depletion
(Figure 1A). In contrast, proportions of CD8T cells were not
fully restored to pre-treatment frequencies during the course of
the experiment. The frequency of bulk CD4 and CD8T cells in
blood increased steadily over time with no overall significant
difference between PTPN22 WT and KO mice (Figure 1A).
CD4T cells showed a transiently higher frequency in PTPN22
KO blood around 2 weeks post-treatment (Figure 1A), and were
slightly elevated in PTPN22 KO spleen, although this difference
did not reach significance (>p = 0.05) (Figure 1B), suggesting
that PTPN22 has a minor impact on the proliferation rate.
Phenotypically T cells acquire an effector memory phenotype
during proliferation in response to homeostatic cues (4). Two
weeks post depletion the frequency of CD44+ cells was slightly
elevated in CD4T cells in comparison to untreated mice where
there was no difference between the genotypes. However, IFNγ
expression was significantly increased in PTPN22KOCD4T cells
indicating that PTPN22 influences the inflammatory potential
of T helper cells and the difference between WT and KO
was particularly pronounced in T cells of mice that underwent
lymphopenia induced proliferation (Figure 1B). Eight weeks
post depletion CD4T cell numbers were comparable to untreated
control mice, whereas CD8T cell counts are still lower in the
depleted groups compared to steady state (Figure 1C).
Phenotypic analysis of the T cells showed increased frequency
of CD44+ and significantly higher expression of Tbet and IFNγ
in PTPN22 KO CD4T cells after they underwent lymphopenia
induced proliferation. Similarly, PTPN22 KO CD8T cells had
significantly more Tbet positive cells following reconstitution
but their proportions of CD44+ and IFNγ+ cells were not
significantly increased. Together these data show that many
weeks after restoration of homeostasis, PTPN22 deficient T cells
have a more activated phenotype than WT cells (Figure 1C).
Whilst activated T cells have the potential to cause (auto-)
inflammation, even after a very long period of more than half
a year post-depletion, PTPN22 KO mice did not develop any
overt signs of autoaggression as determined by signs of weight
loss, indicating inflammatory colitis, a response known to be
exacerbated by loss of PTPN22 following lymphopenic expansion
after transfer of naive T cells into lymphopenic hosts (17) or other
overt post-mortem signs of organ damage (data not shown).
PTPN22-Regulated T Cell Expansion Is
Independent of IL-7Rα Signaling
IL-7 signaling contributes to T cell proliferation in response to
lymphopenia and can mask TCR mediated proliferation (18).
To understand the contribution of PTPN22 in TCR mediated
homeostatic proliferation following Ab depletion, IL-7 signaling
was inhibited by the injection of an IL-7 receptor α blocking
antibody (IL-7Rα Ab) every other day (Figure 2A). Blood
sampling showed that T cells increased in frequency from day
3 to 10 after T cell depletion in both WT and KO mice, with
CD4T cells increasing 6 to 14-fold and CD8T cells 1.5 to 3-fold
(Figure 2B, top panel). Addition of IL-7RαAbmarkedly reduced
proliferation in T cells compared to control mice receiving no
IL-7Rα Ab, such that WT cells increased in proportion by only
1.6 times for CD4 and 1.5 times for CD8 between day 3 and
10. In contrast, even in the presence of IL-7Rα Ab, PTPN22 KO
mice showed a significant increase of CD4 (12.9-fold) and CD8T
cells (3.0-fold) in blood in the same time span (Figures 2B,C).
Analysis of the spleen confirmed significantly higher CD4 and
CD8 cell numbers in PTPN22 KO compared to WT mice when
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FIGURE 1 | PTPN22 controls T cell effector phenotype but does not affect T cell proliferation rate in response Ab-mediated lymphopenia. (A) Scheme of experimental
set-up. T cell expansion was assessed by measuring CD4 and CD8T cell frequencies in blood before T cell depletion throughout the length of the experiment.
Two-way ANOVA with Sidak’s multiple comparison test. N = 4–6 animals per group, one representative experiment out of three independent experiments in total.
Absolute T cell numbers and T cell phenotype analysis in Spleen 2 weeks post depletion (B) and 8 weeks post depletion (C). Each dot represents one animal, data
pooled of two independent experiments in (B) with N = 6–10 animals per group. Data in (A,C) shows one representative experiment out of three independent
experiments in total with N = 4–6 animals per group. Two-way ANOVA with Sidak’s multiple comparison test. n.s. = non-significant. A p < 0.05 was considered
significant. *p < 0.05, **p < 0.01, ***p < 0.001.
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FIGURE 2 | PTPN22 controls T cell proliferation when IL-7 availability is limited. (A) Scheme of experimental set-up. (B) CD4 and CD8T cell frequency in blood 3 and
10 days post T cell depletion in combination with IL-7Rα blockade. Data means with SD shown, N = 7 animals per genotype and time point. Two-way ANOVA with
Sidak’s multiple comparison test. (C) Analysis of T cells number and IFNγ expression in spleen 2 weeks post T cell depletion or T cell depletion in combination with
IL-7 Rα blockade. Each dot represents one animal, N = 7–8 animals per group, shown data is pooled of two independent experiments. Two-way ANOVA with Sidak’s
multiple comparison test. A p < 0.05 was considered significant *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
IL-7R signaling was blocked together with an increase in IFNγ
producing CD4 and CD8T cells (Figures 2B,C). Thus, blockade
of IL-7Rα signaling suggests that PTPN22 KO cells proliferated
faster to TCR-mediated lymphopenic expansion, resulting in
overall higher T cell numbers and an increased capacity to
produce IFNγ 2 weeks after Ab depletion.
Foxp3+ Tregs Are More Resistant to
Ab-Mediated T Cell Depletion
Regulatory T cells are known to suppress T cell proliferation
and activation and are likely to be involved in regulating
lymphopenia-induced proliferation following Ab depletion.
Analysis of different sites and organs showed that in contrast
to the highly efficient depletion of CD4T cells, only between
20 (lymph nodes) and 60% (spleen, blood, peritoneum) of
Tregs were depleted 3 days after antibody injection (Figures 3A,
Supplementary Figure 1C); the overall depletion efficacy in
PTPN22 WT and KO mice was similar. This data suggested
that Ab-mediated CD4 depletion spares a large proportion
of Tregs.
PTPN22 KO animals have increased numbers of
Foxp3+ Treg cells in steady state (17, 19) and 2
weeks post-depletion PTPN22 KOs already showed a
significantly higher proportion of Foxp3 expressing
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FIGURE 3 | Foxp3+ Tregs and IL-10 production are cell-intrinsically controlled by PTPN22 in steady state and LIP. (A) Ab-mediated depletion efficacy of
CD4+Foxp3+ Tregs and CD4+Foxp3− conventional CD4T cells 3 days post anti-CD4 and anti-CD8 injection. Data shown as mean with SD with N = 7 animals per
group. Pooled data of two independent experiments. (B) Proportion and absolute numbers of regulatory T cells 2 weeks after T cell depletion in combination with
(Continued)
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FIGURE 3 | IL-7R blockade and (C) 8 weeks post depletion. Each dot represents one animal. In (B) N = 7–8 animals per group, shown data is pooled of two
independent experiments. In (C) N = 4–6 animals per group, one representative experiment out of three independent experiments. Two-way ANOVA with Sidak’s
multiple comparison test. (D) IL-10 production by CD4T cells, CD4+CD25+ Tregs and CD4+CD25− conventional T cells 2 weeks post depletion. To analyze IL-10
production cells were re-stimulated in presence of Brefeldin A ex vivo. Each dot represents one animal. Each dot represents one animal. N = 6–8 animals per group,
shown data is pooled of two independent experiments. Two-way ANOVA with Sidak’s multiple comparison test. (E) Bone marrow from CD45.1 PTPN22 WT and
CD45.2 PTPN22 KO donor animals was mixed 1:1 and transplanted in into fully irradiated CD45.1/2 PTPN22 WT recipient mice. The Foxp3+ frequency within
PTPN22 WT CD45.1+CD4+ or PTPN22 KO CD45.2+CD4+ cell pool was assessed 15 weeks post transfer. Each dot represents one animal (N = 11), data is pooled
of two independent experiments. A paired t-test was performed to compare PTPN22 WT and KO cells within the same recipient. (F,G) Phenotypical analysis of
Foxp3+ expressing PTPN22 WT CD45.1+CD4+ and PTPN22 KO CD45.2+CD4+ cells from the experiment outlined in (E). Each dot represents one animal (N = 11),
data is pooled of two independent experiments. A paired t-test was performed to compare PTPN22 WT and KO cells within the same recipient. A p < 0.05 was
considered significant *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
cells in comparison to WT mice, independently of IL-
7 availability (Figure 3B). Eight weeks post-depletion,
at which point CD4 homeostasis has been restored,
there were significantly higher numbers of Foxp3+
T cells in PTPN22 KO mice, similar to steady state
untreated control mice (Figure 3C). In addition, a higher
frequency of PTPN22 KO CD4 cells produced IL-10,
and these comprised both CD25+ and CD25− CD4T
cells (Figure 3D).
In order to address whether the increased frequency of
Treg in reconstituting PTPN22 KO mice was influenced by
the presence of other PTPN22 KO hematopoietic cells (e.g.,
dendritic cells or macrophages), lethally irradiated CD45.1/2
PTPN22 WT mice were reconstituted with mixed BM from
CD45.1 PTPN22 WT and CD45.2 PTPN22 KO mice in a 1:1
ratio. In this scenario, newly formed T cells exit the thymus into a
lymphopenic adult host and undergo homeostatic expansion and
we should expect to observe similarly expanded Treg populations
in both WT and PTPN22 KO T cells if this is driven by the
presence of PTPN22 KO hematopoietic cells. Fifteen weeks after
BM transplant we found higher Foxp3+ frequencies within the
PTPN22 KO CD4 pool compared to the corresponding WT
CD4 pool from each individual mouse. These data indicate
that Treg expansion is intrinsically regulated by the presence
of PTPN22, rather than being driven by cytokine production
from other PTPN22 KO hematopoietic cells, which would have
similarly affected both WT and KO Treg generation (Figure 3E).
Further analysis revealed that PTPN22 KO Foxp3+ express
higher levels of CD44 and PTPN22 KO CD25+ produced more
IL-10 in response to re-stimulation, and have a more activated
phenotype (CD44+, CD103+, GITR+ and CD73+) than the
co-generated WT Treg, indicating that their acquisition of
regulatory function and state of activation is also regulated by
PTPN22 (Figures 3F,G).
We hypothesized that the expanded Foxp3+ CD4T cells
may be restraining lymphopenia-induced proliferation in
the context of the PTPN22 KO and attempted to address
this point by specific depletion of Treg using an anti-
CD25 antibody, but were unsuccessful due to the poor
depletion efficacy of this antibody (Supplementary Figure 2).
As an alternative approach we performed co-transfers
of naïve T cells into irradiated recipients to follow the
expansion of PTPN22 KO and WT cells in the absence
of Treg.
PTPN22 KO T Cells Undergo More
Lymphopenic Expansion Than WT T Cells
in the Absence of Tregs
PTPN22 is expressed in all hematopoietic cells and regulates
production of cytokines which could affect peripheral T cell
expansion in response to lymphopenia in the Ab depletion
models we were analyzing. In order to further examine whether
either non-T cells and/or Treg influenced the proliferation
of PTPN22 KO T cells in lymphopenic animals, naïve
CD4+CD62L+CD44−CD25− PTPN22 WT and KO CD4T cells
were transferred into lethally irradiated CD45 congenic C57Bl/6
WT hosts which had been treated with antibiotics to prevent
the fast proliferation stimulated by gut antigens (4). Eleven days
after transferring 2.5 x 105 PTPN22 WT and KO cells at a
ratio of 1:1 there was a change in the ratio of WT:KO to 1:2.
Higher numbers of PTPN22 KO compared to WT CD4T cells
were recovered from lymph nodes and spleen, further confirming
that the influence of PTPN22 on lymphopenia induced T cell
proliferation was cell intrinsic and independent of the presence of
other PTPN22 KO hematopoietic cells (Figure 4A). PTPN22 KO
CD4T cells also had a higher abundance of CD44 expression and
a larger proportion expressed Ki67, a marker for cell proliferation
(Figure 4B), whereas at this time point expression of IFNγ and
IL-10 was comparable between WT and KO cells (Figure 4C).
The transferred T cells were sorted for naïve T cells, so
lacked Treg, but after 11 days a proportion of the input cells
became CD25+. Further analysis showed that up to 11% of
the cells expressed Foxp3 so became iTreg, with significantly
higher contribution from the PTPN22 KO cells to the overall
Foxp3 positive population (Figure 4D). Importantly, equivalent
frequencies of Tregs were found within gated WT or KO CD4
populations, indicating that the increased absolute number of
Foxp3+ PTPN22 KO Treg was a consequence of the overall
higher abundance of PTPN22 KO CD4T cells within the
population of recovered cells (Figure 4E). These data indicate
that the rate of differentiation of naïve T cells into regulatory cells
was not affected by the presence of PTPN22.
PTPN22R619W T Cells Recapitulate the
Response of PTPN22 KO Cells to
Lymphopenia
The previous data suggested that PTPN22 acts in a cell intrinsic
manner to restrict the proliferation and differentiation of WT
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FIGURE 4 | CD4 PTPN22 KO cells outnumber WT when co-transferred into lymphopenic host. (A) Adoptive transfer of naive CD4+CD45.1+ PTPN22 WT and
CD4+CD45.2+ PTPN22 KO cells into lethally irradiated CD45.1/2 WT hosts in a 1:1 ratio. Ratio of transferred cells was assessed 11 days post transfer in spleen and
lymph nodes. (B) Analysis of transferred cells 11 days post transfer for expression of CD44, Ki67 and (C) cytokines IL-10 and IFNγ. (D) Expression of CD25 before
transfer and expression of Foxp3 of transferred CD4T cell population post transfer. (E) Frequency of Foxp3+ expressing cells within the CD4+CD45.1+ PTPN22 WT
cell population in comparison to Foxp3 expressing cells within the CD4+CD45.2+ PTPN22 KO cell population. Data shown in (A–E) is from one representative
experiment of two independent experiments is shown with N = 6 animals. Each dot represents one animal. CD45.1+ PTPN22 WT and CD45.2+ PTPN22 KO cells
obtained from the same host were compared by a paired t-test in (A–E). A p < 0.05 was considered significant *p < 0.05, **p < 0.01, ***p < 0.001.
T cells in a lymphopenic environment. As the PTPN22R620W
variant is found in man rather than a full KO, we tested
whether the equivalent mutation in mouse (R619W) behaved
more similarly to either PTPN22 WT or KO cells in the context
of lymphopenia. First, in order to exclude extrinsic influences
of other hematopoietic populations and in particular Treg on
lymphopenia-induced expansion, we used TCR transgenic OT-
1 Rag-1 KO CD8T cells, and adoptively transferred these
cells into Rag-1 KO lymphopenic hosts. The availability of
transgenic OT-1 CD8T cells expressing CD45 congenic markers
on the three genotypes, PTPN22 WT, KO, and R619W, allowed
us to compare all genotypes in the same environment. The
use of transgenic OT-1 CD8 cells, which express a T cell
receptor that recognizes chicken ovalbumin, precludes responses
to bacterial components from gut which can drive a much
faster homeostatic expansion than the slow proliferation seen in
response to self-peptide:MHC (4). CD8 cells expanded in Rag-
1 KO hosts and 4 weeks after transfer, the initially equal cell
ratio shifted clearly in favor of PTPN22 R619W and PTPN22
KO cells (Figure 5A). PTPN22 KO CD8 cells showed higher
expression of CD44 than PTPN22 WT or PTPN22R619W cells
(Figure 5B). When cells recovered from the lymphopenic mice
were re-stimulated with T4, a low affinity ligand for the OT-
1 T cell receptor, IFNγ production was higher in PTPN22
KO compared to WT OT-1 cells, with PTPN22R619W showing
an intermediate phenotype in comparison to the full knock
out (Figure 5C).
We asked whether the tendency to generation of more Treg
was also evident in the R619W mice by making mixed bone
marrow chimeras between R619W and WT bone marrow using
CD45 allelic markers to distinguish them. Similar to the PTPN22
KO/WT mixed chimeric mice, increased numbers of Tregs
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FIGURE 5 | PTPN22 R619W negatively regulates T cell proliferation in response to lymphopenia. (A) Adoptive transfer of CD45.1 PTPN22 WT, CD45.1/2 PTPN22
R619W and CD45.2 PTPN22 KO CD8 OT-1 cells in a 1:1:1 ratio into lymphopenic Rag-1 KO hosts. Frequency of CD8T cells from the different genotypes were
analyzed 4 weeks after transfer. (B) Analysis of CD44 expression and (C) IFNg expression in response to re-stimulation with T4 peptide 4 weeks post transfer. Data
shown in (A–C) is from one representative experiment out of two independent experiments with N = 5 recipient animals, each dot represents one animal. PTPN22
WT, R619W and KO cells were compared by paired one-way ANOVA. (D) CD45.1 PTPN22 WT and CD45.2 PTPN22 R619W bone marrow was mixed 1:1 and
transplanted in into fully irradiated CD45.2 PTPN22 R619W recipient mice. The Foxp3+ frequency within PTPN22 WT CD45.1+CD4+ or PTPN22 R169W
CD45.2+CD4+ cell pool was assessed 15 weeks post transfer. Each dot represents one animal (N = 13), data is pooled of two independent experiments. A paired
t-test was performed to compare PTPN22 WT and R619W cells within the same recipient. (E) Phenotypical analysis of Foxp3+ expressing PTPN22 WT
CD45.1+CD4+ and PTPN22 KO CD45.2+CD4+ cells from the experiment outlined in (D). Each dot represents one animal (N = 13), data is pooled of two
independent experiments. A paired t-test was performed to compare PTPN22 WT and R619W cells within the same recipient. n.s., non-significant. A p < 0.05 was
considered significant *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
with a more activated phenotype (CD44+, CD103+, GITR+,
CD73+) were recovered with the R619W compared with theWT
genotype (Figures 5D,E).
Together these data show that proliferation induced by
lymphopenia is intrinsically regulated by PTPN22 protein in
both CD4 and CD8T cells. The variant allele PTPN22R619W is
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also defective in regulating lymphopenia-induced proliferation
and CD8T cells expressing this variant also have increased
production of inflammatory cytokines indicating that this
mutation could pose a risk factor for the development of
secondary autoimmunity in man as a sequela to Ab-mediated
lymphodepletion that failed to spare Tregs.
DISCUSSION
In this study we tested the hypothesis that a gene, PTPN22,
identified as a risk factor for autoimmunity might increase
susceptibility to development of autoimmune conditions
following lymphodepletion. Using anti-CD4 and anti-CD8
antibodies in combination we found that severe T cell depletion
was followed by transient proliferation and activation of T
cells until T cell homeostasis was restored. PTPN22 deficient
T cells showed higher expression levels of activation markers,
such as CD44, and produced more pro-inflammatory cytokines
compared to WT T cells. This activated phenotype persisted
amongst PTPN22 KO T cells after restoration of homeostasis
but did not lead to weight loss nor the induction of colitis.
Unexpectedly PTPN22 deficiency had no impact on the rate of
proliferation nor on absolute lymphocyte numbers recovered
after Ab-mediated depletion, provided IL-7 cytokine was
available. IL-7R expression is down-regulated in response
of TCR mediated signaling (20). Thus, IL-7 signaling in
lymphopenic conditions is important for proliferation and
survival when pMHC signals are limited, but dispensable
in conditions of excessive pMHC resources (20, 21). In line
with this, blockade of IL-7R revealed that TCR-mediated
signals alone would drive greater expansion of PTPN22 KO T
cells, as we have shown previously for OT-1 TCR transgenic
cells (12).
The most striking differences we found between the two
genotypes were increased levels of Tregs and IL-10 producing
T cells in PTPN22 KO compared to WT mice from 2 weeks
post depletion. IL-10 was shown previously to be critical for
Treg control of LIP (22), and in a study by Winstead et al.
Tregs were shown to be important to control colitis in response
to lymphopenia (23). Tregs were more abundant in absolute
number and in relative frequency within the CD4T cell pool
in PTPN22 KO mice 8 weeks post-depletion. Previous studies
in PTPN22 KO mice have shown elevated Treg levels in steady
state and found that PTPN22 also regulates Treg function (17,
19). By generating mixed bone marrow chimeric we showed
that Tregs expanded more within the PTPN22 KO population
indicating that Treg differentiation is unaffected by the presence
of other PTPN22 KO hematopoietic cells and is, therefore,
a cell intrinsic effect. Experiments comparing the conversion
of PTPN22 WT and KO CD4T cells into Foxp3 expressing
regulatory cells suggested that PTPN22 mediated regulation of
TCR signal strength is important for Treg differentiation in vitro
and in vivo 45 days after transfer into Rag-1 KO recipient mice
(24). Together these data suggest that the increase in PTPN22
KOTregs comes primarily from peripheral expansion rather than
de novo thymic output or enhanced iTreg generation.
Regulatory T cells have been shown to be important
to keep conventional T cells in check and prevent further
autoimmunological complications in lymphopenic conditions.
Suppression of antigen mediated T cell proliferation by Tregs
through CTLA-4 mediated downregulation of costimulatory
CD80/CD86 expression on APCs and thus modulation of CD28
signaling is well-described (25, 26). The transfer of CTLA-
4 deficient Tregs into Rag1 KO lymphopenic hosts prior to
conventional CD4 infusion impairs T cell proliferation partially
suggesting that other CTLA-4-independent mechanisms are
involved (27). Alemtuzumab treatment in man (28) or in a
humanized mouse model (29), depleted Foxp3+ Tregs less
efficiently than conventional CD4T cells similar to anti-CD4
antibody treatment in our experiments. We found that by 2
weeks post depletion the relative frequency of CD25+Foxp3+
expressing Tregs within the CD4T cell pool was similar to the
ratio of Tregs to conventional T cells under steady state. So
far little is known about how lymphopenia may alter immune
regulatory mechanisms such as the Treg compartment and
how the reconstitution of regulatory T cells is regulated after
irradiation and/or Ab-mediated depletion. A recent study of
Delmarre et al. showed that autologous HSCT results in a
diversification of the TCR repertoire suggesting that Tregs
are functionally renewed by HSCT which might contribute to
clinical improvement (30). Moreover, the success of autologous
HSCT as a treatment for juvenile idiopathic arthritis has been
shown to correlate with increased Treg frequency together with
reprogramming of autoreactive T cells (31). In contrast, Jones
et al. found that Treg suppressive capacity is improved 3–4 years
after Alemtuzumab treatment in MS patients whether or not
they developed secondary autoimmune disease, suggesting Treg
abundance is not a determining factor in this instance (7, 28).
Given that PTPN22 is a major risk allele for autoimmunity
and its role in the negative regulation of T cell activation in
response to antigens with a weak TCR affinity, such as self-
antigens, we hypothesized that functional PTPN22 might be
critical for “safe” T cell restoration after a lymphopenic insult.
The association of the PTPN22 R620W SNP with various
autoimmune diseases suggests a regulatory role of functional
PTPN22 for T cell activation in human. In mouse the R619W
point mutation in the Ptpn22 gene resembles the full knock-out
suggesting that R619W is a loss of function mutation (32, 33).
Interestingly neither the PTPN22 R619W nor the full PTPN22
KO mouse show any signs of autoinflammation or spontaneous
development of autoimmunity in steady state on the C57Bl/6
background, despite the increased numbers of lymphocytes and
their activated phenotype (17, 32). This may be a consequence
of the relative resistance of the C57Bl/6 background to the
development of autoimmunity as the 129 mouse background, in
contrast, permitted the spontaneous development of disease in
PTPN22R619W knock-in mice (33).
Higher TCR affinity might lead to chronic signaling in
PTPN22 KO T cells, which could cause the upregulation of
co-inhibitory receptors and thereby limit excessive proliferation
in absence of PTPN22. The co-inhibitory receptor PD-1 is
known to be upregulated in response to T cell activation and
negatively regulates T cell function. Transgenic male antigen
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specific PD-1 KO CD4T cells outnumbered WT cells when
adoptively transferred into female Rag1 KO, suggesting that PD-
1 regulates tonic pMHC signaling and LIP (21). In contrast to
PTPN22, PD-1 controlled proliferation but had no impact on
IFNγ production indicating that negative regulation by PD-1
differs from PTPN22 and that not all co-factors have equal ability
to cause autoimmunity. Notably the study of Jones et al. showed
that CD4 and CD8 cell reconstitution was similar between
patients with and without secondary autoimmunity, suggesting
that the rate of T cell reconstitution and T cell number itself may
not be a useful measurement to predict outcome in Alemtuzumab
treated MS patients (7).
Based on our findings we conclude that antibody mediated
T cell lymphopenia does not trigger overt auto-aggression in
PTPN22 KO mice although PTPN22 deficient T cells showed
a pronounced effector phenotype. High abundance of Tregs
and IL-10 producing cells in PTPN22 KO mice have been
previously associated with increased tolerance in a model of
pancreatic islet transplantation and might suppress excessive
T cell proliferation and keep activated T cell clones in check
(34). T cell numbers were significantly higher in PTPN22 KO
than in WT mice when IL-7 signaling was blocked indicating
that the availability of IL-7 can mask dysregulated self-peptide
MHC/TCR mediated proliferation during lymphopenia. IL-
7 could be an important factor for T cell expansion in
a TCR-signaling independent manner which might promote
the expansion of a more diverse repertoire. Although the
contribution and the exact mechanism of suppression by
Tregs in lymphopenia induced proliferation is unclear, our
results suggest that sparing regulatory T cell in therapies
using lymphocytes depleting antibodies might be an efficient
strategy to prevent lymphopenia mediated autoinflammatory
reactions. The observation that PTPN22R619W mice had a
similar expansion of Tregs to the PTPN22-KO mice, raises the
intriguing possibility that in man, carrying the PTPN22R620W
allele might even be protective against secondary autoimmunity
following therapeutic Ab depletion, rather than being an
increased risk factor as we originally hypothesized. Conversely,
enhanced T cell activation mediated by LIP in absence of
PTPN22 could promote tumor immunity and be attractive for
cancer therapies.
DATA AVAILABILITY STATEMENT
The datasets generated for this study are available on request to
the corresponding author.
ETHICS STATEMENT
The animal study was reviewed and approved by UK Home
Office and performed in accordance with the institutional and
ethical guidelines of the University of Edinburgh.
AUTHOR CONTRIBUTIONS
JK designed and performed experiments, analyzed data, and
wrote the manuscript. DW designed the PTPN22 R619Wmutant
mouse strain. AC provided intellectual input into the project and
design of the PTPN22 R619W mouse. BM designed the OST-
tagged Ptpn22 gene construct and provided OST-tagged PTPN22
mouse. RZ led the overall project, designed experiments, and
wrote the manuscript.
FUNDING
This work was funded by a Wellcome Trust Investigator Award
WT205014/Z/16/Z to RZ, as well as by anARUK/Versus Arthritis
grant 20525 awarded to RZ and AC.
ACKNOWLEDGMENTS
We thankMartinWaterfall for helping with cell sorting, Fredéric
Fiore for supervising the construction of PTPN22 OST-tagged
mice, and Biological Services for technical support. We are very
grateful for helping hands on big days: Nicola Logan, Céline
Garcia and Marta Trüb. Margo Chase-Topping gave advice on
statistical data analysis.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fimmu.
2020.00052/full#supplementary-material
REFERENCES
1. King C, Ilic A, Koelsch K, Sarvetnick N. Homeostatic expansion of T cells
during immune insufficiency generates autoimmunity. Cell. (2004) 117:265–
77. doi: 10.1016/S0092-8674(04)00335-6
2. Le Saout C, Mennechet S, Taylor N, Hernandez J. Memory-like CD8+
and CD4+ T cells cooperate to break peripheral tolerance under
lymphopenic conditions. Proc Natl Acad Sci USA. (2008) 105:19414–
9. doi: 10.1073/pnas.0807743105
3. Bourgeois C, Stockinger B. CD25+CD4+ regulatory T cells and
memory T cells prevent lymphopenia-induced proliferation of
naive T cells in transient states of lymphopenia. J Immunol. (2006)
177:4558–66. doi: 10.4049/jimmunol.177.7.4558
4. Surh CD, Sprent J. Homeostasis of naive and memory T cells. Immunity.
(2008) 29:848–62. doi: 10.1016/j.immuni.2008.11.002
5. Golshayan D, Pascual M. Tolerance-inducing immunosuppressive
strategies in clinical transplantation: an overview. Drugs. (2008)
68:2113–30. doi: 10.2165/00003495-200868150-00004
6. Haudebourg T, Poirier N, Vanhove B. Depleting T-cell subpopulations
in organ transplantation. Transpl Int. (2009) 22:509–18.
doi: 10.1111/j.1432-2277.2008.00788.x
7. Jones JL, Thompson SA, Loh P, Davies JL, Tuohy OC, Curry AJ,
et al. Human autoimmunity after lymphocyte depletion is caused by
homeostatic T-cell proliferation. Proc Natl Acad Sci USA. (2013) 110:20200–
5. doi: 10.1073/pnas.1313654110
8. Bottini N, Peterson EJ. Tyrosine phosphatase PTPN22: multifunctional
regulator of immune signaling, development, and disease.Annu Rev Immunol.
(2014) 32:83–119. doi: 10.1146/annurev-immunol-032713-120249
9. Stanford SM, Bottini N. PTPN22: the archetypal non-HLA autoimmunity
gene. Nat Rev Rheumatol. (2014) 10:602–11. doi: 10.1038/nrrheum.2014.109
Frontiers in Immunology | www.frontiersin.org 12 January 2020 | Volume 11 | Article 52
Knipper et al. PTPN22 Shapes Immune Reconstitution
10. Burn GL, Svensson L, Sanchez-Blanco C, Saini M, Cope AP.Why is PTPN22 a
good candidate susceptibility gene for autoimmune disease? FEBS Lett. (2011)
585:3689–98. doi: 10.1016/j.febslet.2011.04.032
11. Hasegawa K, Martin F, Huang G, Tumas D, Diehl L, Chan AC. PEST domain-
enriched tyrosine phosphatase (PEP) regulation of effector/memory T cells.
Science. (2004) 303:685–9. doi: 10.1126/science.1092138
12. Salmond RJ, Brownlie RJ, Morrison VL, Zamoyska R. The tyrosine
phosphatase PTPN22 discriminates weak self peptides from strong agonist
TCR signals. Nat Immunol. (2014) 15:875–83. doi: 10.1038/ni.2958
13. Bray C, Wright D, Haupt S, Thomas S, Stauss H, Zamoyska R.
Crispr/Cas mediated deletion of PTPN22 in Jurkat T cells enhances
TCR signaling and production of IL-2. Front Immunol. (2018)
9:2595. doi: 10.3389/fimmu.2018.02595
14. Junttila MR, Saarinen S, Schmidt T, Kast J, Westermarck J. Single-
step Strep-tag purification for the isolation and identification
of protein complexes from mammalian cells. Proteomics. (2005)
5:1199–203. doi: 10.1002/pmic.200400991
15. Voisinne G, Garcia-Blesa A, Chaoui K, Fiore F, Bergot E, Girard L, et al. Co-
recruitment analysis of the CBL and CBLB signalosomes in primary T cells
identifies CD5 as a key regulator of TCR-induced ubiquitylation.Mol Syst Biol.
(2016) 12:876. doi: 10.15252/msb.20166837
16. Pettitt SJ, Liang Q, Rairdan XY, Moran JL, Prosser HM, Beier DR, et al. Agouti
C57BL/6N embryonic stem cells for mouse genetic resources. Nat Methods.
(2009) 6:493–5. doi: 10.1038/nmeth.1342
17. Brownlie RJ, Miosge LA, Vassilakos D, Svensson LM, Cope A, Zamoyska R.
Lack of the phosphatase PTPN22 increases adhesion of murine regulatory
T cells to improve their immunosuppressive function. Sci Signal. (2012)
5:ra87. doi: 10.1126/scisignal.2003365
18. Takada K, Jameson SC. Naive T cell homeostasis: from awareness of space to
a sense of place. Nat Rev Immunol. (2009) 9:823–32. doi: 10.1038/nri2657
19. Maine CJ, Hamilton-Williams EE, Cheung J, Stanford SM, Bottini N, Wicker
LS, et al. PTPN22 alters the development of regulatory T cells in the thymus. J
Immunol. (2012) 188:5267–75. doi: 10.4049/jimmunol.1200150
20. Koenen P, Heinzel S, Carrington EM,Happo L, AlexanderWS, Zhang JG, et al.
Mutually exclusive regulation of T cell survival by IL-7R and antigen receptor-
induced signals. Nat Commun. (2013) 4:1735. doi: 10.1038/ncomms2719
21. Ellestad KK, Lin J, Boon L, Anderson CC. PD-1 controls tonic signaling and
lymphopenia-induced proliferation of T lymphocytes. Front Immunol. (2017)
8:1289. doi: 10.3389/fimmu.2017.01289
22. Annacker O, Pimenta-Araujo R, Burlen-Defranoux O, Barbosa TC, Cumano
A, Bandeira A. CD25+ CD4+ T cells regulate the expansion of peripheral
CD4T cells through the production of IL-10. J Immunol. (2001) 166:3008–
18. doi: 10.4049/jimmunol.166.5.3008
23. Winstead CJ, Fraser JM, Khoruts A. Regulatory CD4+CD25+Foxp3+
T cells selectively inhibit the spontaneous form of lymphopenia-
induced proliferation of naive T cells. J Immunol. (2008)
180:7305–17. doi: 10.4049/jimmunol.180.11.7305
24. Fousteri G, Jofra T, Debernardis I, Stanford SM, Laurenzi A, Bottini N, et al.
The protein tyrosine phosphatase PTPN22 controls forkhead box protein
3 T regulatory cell induction but is dispensable for T helper type 1 cell
polarization. Clin Exp Immunol. (2014) 178:178–89. doi: 10.1111/cei.12393
25. Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z,
et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science. (2008)
322:271–5. doi: 10.1126/science.1160062
26. Yi J, Jung J, Hong SW, Lee JY, Han D, Kim KS, et al. Unregulated antigen-
presenting cell activation by T cells breaks self tolerance. Proc Natl Acad Sci
USA. (2019) 116:1007–16. doi: 10.1073/pnas.1818624116
27. Bolton HA, Zhu E, Terry AM, Guy TV, Koh WP, Tan SY, et al. Selective
Treg reconstitution during lymphopenia normalizes DC costimulation
and prevents graft-versus-host disease. J Clin Invest. (2015) 125:3627–
41. doi: 10.1172/JCI76031
28. Cox AL, Thompson SA, Jones JL, Robertson VH, Hale G,
Waldmann H, et al. Lymphocyte homeostasis following therapeutic
lymphocyte depletion in multiple sclerosis. Eur J Immunol. (2005)
35:3332–42. doi: 10.1002/eji.200535075
29. Hu Y, Turner MJ, Shields J, Gale MS, Hutto E, Roberts BL,
et al. Investigation of the mechanism of action of alemtuzumab
in a human CD52 transgenic mouse model. Immunology. (2009)
128:260–70. doi: 10.1111/j.1365-2567.2009.03115.x
30. Delemarre EM, van den Broek T, Mijnheer G, Meerding J, Wehrens EJ, Olek
S, et al. Autologous stem cell transplantation aids autoimmune patients by
functional renewal and TCR diversification of regulatory T cells. Blood. (2016)
127:91–101. doi: 10.1182/blood-2015-06-649145
31. de Kleer I, Vastert B, Klein M, Teklenburg G, Arkesteijn G, Yung GP,
et al. Autologous stem cell transplantation for autoimmunity induces
immunologic self-tolerance by reprogramming autoreactive T cells and
restoring the CD4+CD25+ immune regulatory network. Blood. (2006)
107:1696–702. doi: 10.1182/blood-2005-07-2800
32. Zhang J, Zahir N, Jiang Q, Miliotis H, Heyraud S, Meng X, et al.
The autoimmune disease-associated PTPN22 variant promotes calpain-
mediated Lyp/Pep degradation associated with lymphocyte and dendritic cell
hyperresponsiveness. Nat Genet. (2011) 43:902–7. doi: 10.1038/ng.904
33. Dai X, James RG, Habib T, Singh S, Jackson S, Khim S, et al. A
disease-associated PTPN22 variant promotes systemic autoimmunity in
murine models. J Clin Invest. (2013) 123:2024–36. doi: 10.1172/JCI
66963
34. Fousteri G, Jofra T, Di Fonte R, Gagliani N, Morsiani C, Stabilini A,
et al. Lack of the protein tyrosine phosphatase PTPN22 strengthens
transplant tolerance to pancreatic islets in mice.Diabetologia. (2015) 58:1319–
28. doi: 10.1007/s00125-015-3540-9
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2020 Knipper, Wright, Cope, Malissen and Zamoyska. This is an open-
access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) and the copyright owner(s) are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Immunology | www.frontiersin.org 13 January 2020 | Volume 11 | Article 52
